most of the interesting data on OV at this point is based on immune stimulation rather than 'oncolytic' activity, thought they are intimately related. They have

most of the interesting data on OV at this point is based on immune stimulation rather than 'oncolytic' activity, thought they are intimately related. They have some of the best combination data with anti-PD1 at this point- some clinical data indicates they double response rates with no toxicity (vs anti-PD-1 anti-CTLA4 combinations which double responses rates, but most patients drop off therapy due to tox.). For years, these agents had been sold as ' viruses melting away tumors' which isn't really what is going on. as Immune oncology is better understood, they appear to be pretty good way to get the immune system activated in the tumor environment.